New hope for refractory lymphoma: tailored drug cocktail targets resistant cancer
NCT ID NCT07493330
First seen Apr 13, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This study tests a personalized combination of drugs for people with a type of lymphoma (PTCL) that did not respond to initial chemotherapy. Researchers will use genetic information from each patient's tumor to select the best drug combination, including an experimental drug called zeprumetostat. The goal is to see if this approach is safe and effective in controlling the cancer. About 86 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PTCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.